Cargando…

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

The evaluation of PD‐L1 expression alone has limitations in predicting clinical outcome in immune‐checkpoint inhibitors (ICI). This study aimed to evaluate the predictive and prognostic effects of the presence of various immune cells in pretreatment tissue samples and to identify determinants associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ku, Bo Mi, Kim, Youjin, Lee, Kyoung Young, Kim, Sang‐Yeob, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Tumor immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248238/ https://www.ncbi.nlm.nih.gov/pubmed/33506525 http://dx.doi.org/10.1002/eji.202048966

Ejemplares similares

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
por: Kim, Hyera, et al.
Publicado: (2020)

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
por: Park, Sehhoon, et al.
Publicado: (2022)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
por: Park, Sehhoon, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery
por: Lee, Min Ho, et al.
Publicado: (2021)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts Suppress CD8(+) T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
por: Jenkins, Liam, et al.
Publicado: (2022)

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Koh, Jiae, et al.
Publicado: (2020)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
por: Ku, Bo Mi, et al.
Publicado: (2018)

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
por: Jung, Hyunchul, et al.
Publicado: (2019)

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
por: Won, Ji Eun, et al.
Publicado: (2022)

GCT-51. IMMUNE CHECKPOINT MOLECULES AND TUMOR INFILTRATING LEUKOCYTES IN THE TUMOR MICROENVIRONMENT ARE ASSOCIATED WITH THE GROWTH OF INTRACRANIAL GERMINOMAS
por: Nishimoto, Masaaki, et al.
Publicado: (2020)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2016)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells
por: Lee, Se‐Hoon, et al.
Publicado: (2023)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma
por: Jeong, Hyoung-oh, et al.
Publicado: (2022)

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
por: Kim, Hongsik, et al.
Publicado: (2022)

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up
por: Oswald, Eva, et al.
Publicado: (2022)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Incidence and Phenotypes of Endocrinopathies in Association With Immune Checkpoint Inhibitors: The Experience of Integrated Health Network
por: Mehmood, Hassan, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
por: Pani, Fabiana, et al.
Publicado: (2022)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers
por: Kim, Jung Ho, et al.
Publicado: (2021)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_07lio2836t0esb6lhaf6nk06th